Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive SummaryNew CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.
You may also be interested in...
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.